SLC22A3 and carcinoma of esophagus: Several differential editing events have been reported in tumorigenesis, such as antizyme inhibitor 1 (AZIN1) editing in liver cancer [1], cell division cycle 14B (CDC14B) editing in glioblastoma [25], RAS homolog family member Q (RHOQ) editing in colorectal cancer [26], gamma-aminobutyric acid type A receptor subunit aplha3 (GABRA3) editing in breast cancer [27], solute carrier family 22 member 3 (SLC22A3) and insulin-like growth factor binding protein 7 (IGFBP7) editing in oesophageal cancer [28] and podocalyxin-like 1 (PODXL) editing in gastric cancer [29].